全文获取类型
收费全文 | 126930篇 |
免费 | 7153篇 |
国内免费 | 1090篇 |
专业分类
耳鼻咽喉 | 1951篇 |
儿科学 | 1913篇 |
妇产科学 | 1872篇 |
基础医学 | 20228篇 |
口腔科学 | 3075篇 |
临床医学 | 11780篇 |
内科学 | 22690篇 |
皮肤病学 | 3966篇 |
神经病学 | 10304篇 |
特种医学 | 7252篇 |
外科学 | 16618篇 |
综合类 | 530篇 |
现状与发展 | 3篇 |
一般理论 | 27篇 |
预防医学 | 6686篇 |
眼科学 | 3188篇 |
药学 | 11398篇 |
中国医学 | 1457篇 |
肿瘤学 | 10235篇 |
出版年
2023年 | 905篇 |
2022年 | 2713篇 |
2021年 | 4392篇 |
2020年 | 2106篇 |
2019年 | 2943篇 |
2018年 | 3673篇 |
2017年 | 2988篇 |
2016年 | 3899篇 |
2015年 | 5441篇 |
2014年 | 6438篇 |
2013年 | 7500篇 |
2012年 | 11241篇 |
2011年 | 10774篇 |
2010年 | 6165篇 |
2009年 | 5290篇 |
2008年 | 7529篇 |
2007年 | 7151篇 |
2006年 | 6463篇 |
2005年 | 5980篇 |
2004年 | 5212篇 |
2003年 | 4536篇 |
2002年 | 3902篇 |
2001年 | 3032篇 |
2000年 | 2786篇 |
1999年 | 2136篇 |
1998年 | 905篇 |
1997年 | 666篇 |
1996年 | 507篇 |
1995年 | 450篇 |
1994年 | 388篇 |
1993年 | 331篇 |
1992年 | 746篇 |
1991年 | 695篇 |
1990年 | 638篇 |
1989年 | 555篇 |
1988年 | 464篇 |
1987年 | 466篇 |
1986年 | 332篇 |
1985年 | 368篇 |
1984年 | 261篇 |
1983年 | 191篇 |
1982年 | 132篇 |
1981年 | 168篇 |
1980年 | 128篇 |
1979年 | 222篇 |
1978年 | 162篇 |
1976年 | 132篇 |
1975年 | 120篇 |
1974年 | 139篇 |
1973年 | 119篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
81.
82.
Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. 总被引:1,自引:0,他引:1
Beta-adrenergic receptor density on T cells from healthy humans is greatest on suppressor cells (CD8+, CD28-) and the effect of catecholamines, secreted by the sympathetic nervous system, predominates on this subset. The sympathetic skin response, a measure of sympathetic nervous system function, is absent in most patients with chronic progressive multiple sclerosis (MS). We measured beta-adrenergic receptor density on suppressor cells, cytotoxic cells, and monocytes from patients with chronic progressive MS and healthy control subjects. Control receptor density on suppressor cells was 2.8 +/- 0.3 fmol/10(6) cells versus a density of 5.1 +/- 0.7 fmol/10(6) cells for patients. Cytotoxic cell (CD8+, CD28+) receptor density was 1.4 +/- 0.4 fmol/10(6) cells in control subjects and 0.9 +/- 0.3 fmol/10(6) cells in the patients. Monocytes displayed beta-adrenergic receptor densities of 2.6 +/- 0.4 fmol/10(6) cells in normal individuals and 2.7 +/- 0.4 fmol/10(6) cells in the patient group. CD8 lymphocyte beta-adrenergic receptor densities in patients with relapsing-remitting and those with stable MS were not different from control values, yet were significantly less than the values for patients with chronic progressive MS. We find that mononuclear cells from healthy control subjects and patients with chronic progressive MS proliferate in response to 200 units/ml of recombinant human interleukin-2 (IL-2) similarly. However, IL-2 treatment increased beta-adrenergic receptor density on normal mononuclear cells, but failed to increase it on mononuclear cells from patients with chronic progressive MS.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
83.
84.
85.
86.
87.
88.
Diseases like rotavirus afflict both upper- and lower-income countries, but most serious illnesses and deaths occur among the latter. It is a vital public health issue that vaccines for these types of global diseases can recover research and development (R&D) costs from high-priced markets quickly so that manufacturers can offer affordable prices to lower-income nations. Cost recovery depends on how high R&D costs are, and this study attempts to replace high, unverified estimates with lower, more verifiable estimates for two new vaccines, RotaTeq (Merck) and Rotarix (GlaxoSmithKline or GSK), based on detailed searches of public information and follow-up interviews with senior informants. We also offer a new perspective on “cost of capital” as a claim for recovery from public bodies. Our estimates suggest that companies can recover all fixed costs quickly from affluent markets and thus can offer these vaccines to lower-income countries at prices they can afford. Better vaccines are a shared project between companies and public health agencies; greater transparency and consistency in reporting of R&D costs is needed so that fair prices can be established. 相似文献
89.
90.